Glimepiride Aurobindo

Glimepiride Aurobindo is a prescription oral tablet that contains the active ingredient glimepiride, a sulfonylurea class drug used to improve blood glucose control in adults with type 2 diabetes mellitus. Manufactured by Aurobindo Pharma and marketed in the European Union, the product is supplied for oral administration. It is intended for use under the supervision of a qualified healthcare professional as part of a comprehensive diabetes management plan.

Glimepiride Aurobindo is indicated for the management of hyperglycemia in patients with type 2 diabetes mellitus when diet, exercise, and other oral agents are insufficient.

- As monotherapy in adults with type 2 diabetes inadequately controlled by lifestyle measures. - In combination with metformin when additional glycemic reduction is needed. - As part of a fixed‑dose combination regimen with other oral antidiabetic agents, if prescribed. - To help achieve target HbA1c levels as determined by a healthcare provider. - May be used in patients with renal impairment with dose adjustment as advised.

The safety profile of glimepiride, the active ingredient of Glimepiride Aurobindo, may cause a range of adverse reactions that are categorized as common (generally mild and reversible) or serious (potentially life‑threatening and requiring immediate medical attention). These events may vary with dose, patient characteristics, and concomitant therapies.

Common: - Mild hypoglycemia, especially when meals are skipped or delayed. - Weight gain due to increased insulin activity. - Gastrointestinal discomfort such as nausea, abdominal pain, or dyspepsia. - Skin reactions like rash, pruritus, or mild erythema. - Dizziness or headache, usually transient. - Fatigue or weakness, generally mild.

Serious: - Severe hypoglycemia leading to loss of consciousness, seizures, or accidents. - Allergic reactions including angioedema, anaphylaxis, or severe skin blistering. - Pancreatitis or other serious hepatic events (rare). - Hematologic abnormalities such as leukopenia, thrombocytopenia, or anemia.

When prescribing Glimepiride Aurobindo, clinicians should consider several precautionary measures to minimize risk and ensure appropriate use.

- Assess renal and hepatic function before initiation and adjust dose if impairment is present. - Review patient history for sulfonylurea allergy or prior severe hypoglycemia. - Use caution in elderly patients due to increased susceptibility to hypoglycemia. - Advise patients to maintain regular meal patterns and avoid excessive alcohol consumption. - Monitor blood glucose regularly, especially during therapy changes or sick days. - Consider pregnancy and lactation status; glimepiride is generally avoided unless benefits outweigh risks.

Glimepiride Aurobindo can interact with other medicines, altering its glucose‑lowering effect or increasing the risk of adverse events.

Avoid: - Concomitant use with other sulfonylureas or insulin secretagogues, which may cause additive hypoglycemia. - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that can raise glimepiride plasma concentrations. - Meglitinides (e.g., repaglinide) as combined use may increase hypoglycemia risk.

Use with caution: - Beta‑blockers, which may mask hypoglycemia symptoms. - Thiazide diuretics, which can potentiate hypoglycemic episodes. - Oral corticosteroids or atypical antipsychotics, which may reduce glimepiride efficacy. - Anticoagulants such as warfarin, requiring closer INR monitoring. - Macrolide antibiotics (e.g., erythromycin) may increase glimepiride levels; monitor glucose closely.